TY - JOUR
T1 - Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease
AU - Clarke, John D.
AU - Novak, Petr
AU - Lake, April D.
AU - Hardwick, Rhiannon N.
AU - Cherrington, Nathan J.
N1 - Funding Information:
Funding information National Institutes of Health Grants [DK068039] and [ES006694]; National Institute of Environmental Health Science Toxicology Training Grant [ES007091]; Liver Tissue Cell Distribution System National Institute of Health Contract [N01-DK-7-0004/HHSN267200700004C]. We thank the Bioinformatics and Statistical Consortium at the University of Arizona. We would also like to thank the National Institutes of Health-funded Liver Tissue Cell Distribution System liver tissue samples and those people specifically involved, Marion Namenwirth (University of Minnesota), Melissa Thompson (Virginia Commonwealth University), and Dr. Stephen C. Strom and Kenneth Dorko (University of Pittsburgh).
Publisher Copyright:
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2017/7
Y1 - 2017/7
N2 - Background & Aims: N-linked glycosylation of proteins is critical for proper protein folding and trafficking to the plasma membrane. Drug transporters are one class of proteins that have reduced function when glycosylation is impaired. N-linked glycosylation of plasma proteins has also been investigated as a biomarker for several liver diseases, including non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to assess the transcriptomic expression of genes involved in protein processing and glycosylation, and to determine the glycosylation status of key drug transporters during human NAFLD progression. Methods: Human liver samples diagnosed as healthy, steatosis, and non-alcoholic steatohepatitis (NASH) were analysed for gene expression of glycosylation-related genes and for protein glycosylation using immunoblot. Results: Genes involved in protein processing in the ER and biosynthesis of N-glycans were significantly enriched for down-regulation in NAFLD progression. Included in the down regulated N-glycan biosynthesis category were genes involved in the oligosaccharyltransferase complex, N-glycan quality control, N-glycan precursor biosynthesis, N-glycan trimming to the core, and N-glycan extension from the core. N-glycan degradation genes were unaltered in the progression to NASH. Immunoblot analysis of the uptake transporters organic anion transporting polypeptide-1B1 (OATP1B1), OATP1B3, OATP2B1, and Sodium/Taurocholate Co-transporting Polypeptide (NTCP) and the efflux transporter multidrug resistance-associated protein 2 (MRP2) demonstrated a significant loss of glycosylation following the progression to NASH. Conclusions: These data suggest that the loss of glycosylation of key uptake and efflux transporters in humans NASH may influence transporter function and contribute to altered drug disposition observed in NASH.
AB - Background & Aims: N-linked glycosylation of proteins is critical for proper protein folding and trafficking to the plasma membrane. Drug transporters are one class of proteins that have reduced function when glycosylation is impaired. N-linked glycosylation of plasma proteins has also been investigated as a biomarker for several liver diseases, including non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to assess the transcriptomic expression of genes involved in protein processing and glycosylation, and to determine the glycosylation status of key drug transporters during human NAFLD progression. Methods: Human liver samples diagnosed as healthy, steatosis, and non-alcoholic steatohepatitis (NASH) were analysed for gene expression of glycosylation-related genes and for protein glycosylation using immunoblot. Results: Genes involved in protein processing in the ER and biosynthesis of N-glycans were significantly enriched for down-regulation in NAFLD progression. Included in the down regulated N-glycan biosynthesis category were genes involved in the oligosaccharyltransferase complex, N-glycan quality control, N-glycan precursor biosynthesis, N-glycan trimming to the core, and N-glycan extension from the core. N-glycan degradation genes were unaltered in the progression to NASH. Immunoblot analysis of the uptake transporters organic anion transporting polypeptide-1B1 (OATP1B1), OATP1B3, OATP2B1, and Sodium/Taurocholate Co-transporting Polypeptide (NTCP) and the efflux transporter multidrug resistance-associated protein 2 (MRP2) demonstrated a significant loss of glycosylation following the progression to NASH. Conclusions: These data suggest that the loss of glycosylation of key uptake and efflux transporters in humans NASH may influence transporter function and contribute to altered drug disposition observed in NASH.
KW - N-linked glycosylation
KW - Non-alcoholic steatohepatitis
KW - drug transporters
KW - hepatobiliary drug disposition
UR - http://www.scopus.com/inward/record.url?scp=85012965467&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012965467&partnerID=8YFLogxK
U2 - 10.1111/liv.13362
DO - 10.1111/liv.13362
M3 - Article
C2 - 28097795
AN - SCOPUS:85012965467
VL - 37
SP - 1074
EP - 1081
JO - Liver International
JF - Liver International
SN - 1478-3223
IS - 7
ER -